The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
about
FGFR3-TACC3 fusion in solid tumors: mini reviewDevelopmental therapeutics for inflammatory breast cancer: Biology and translational directionsInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationDrug-sensitive FGFR3 mutations in lung adenocarcinoma.Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinomaMetformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cellsThe Conundrum of Genetic "Drivers" in Benign Conditions.FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.FGFR-targeted therapeutics for the treatment of breast cancer.FGFR-TACC gene fusions in human glioma.Advances and challenges in targeting FGFR signalling in cancer.Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment.Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures.Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model.Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.Inferring expressed genes by whole-genome sequencing of plasma DNA.Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients.Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer.Targeted Therapies Against Growth Factor Signaling in Breast Cancer.Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.Different stages in drug development for muscle-invasive bladder cancer.Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.Mechanisms of receptor tyrosine kinase activation in cancer.The integration of genomics testing and functional proteomics in the era of personalized medicine.
P2860
Q26740578-BF6E9493-798E-4D25-969F-36306708C865Q28075322-C11E27AF-1215-472B-AAC0-296BFB152B93Q28079309-288D300D-B3DF-4599-8CC3-5281C5774932Q33564782-F407616D-F71D-4657-9536-162D835A2616Q33648854-67FCCC1E-3410-42BB-96AC-AC572B5D4BC2Q33888883-721BC0B0-FEC7-4A10-AB94-858CE9F30010Q37225270-6DB3747C-4173-4A9E-98DD-E5F1D875E7C1Q37245787-CAA7930B-3BAF-4A52-94F2-85AD51A451D4Q37462489-EDB70CD7-9FED-49D4-AEC7-F46C0D09A512Q37622191-165A2C0E-0A4B-4088-9FB2-A77B2E58CB41Q37628912-F6FA855D-60CC-409A-A461-356CF6E96475Q37687627-593A8E85-1ED8-47BB-966E-0058F716F755Q37701569-39730004-4CE9-455C-B2D1-4578F85F49E5Q37706844-91EEE812-5990-400F-8914-3D2DA9033005Q38766035-84F06309-438D-4F3E-BF87-6E50E123E0A9Q39010445-4E3DE794-A447-4892-8A4A-49D6C7EB4C84Q39183442-80D8A0A1-0739-4D1E-9199-4F657EC925C0Q39226762-A167E583-CE56-484B-B0C4-5D37B5E3FE38Q39282670-4595E31C-E8A7-4E3C-9CB4-8B74F49DC0D1Q39352697-EEAEA457-7F9C-456A-BBC3-2EACB3FCD7F6Q39908219-1B959158-87C7-4B6C-9DE1-A8A64C539652Q40417660-1642B55C-737B-4F8F-A6F7-360817F2BD71Q41243144-43ED28FA-8978-4315-B2AD-DBF9694650CAQ41511970-34385510-720F-4C83-84D1-7CB1E678688AQ41525071-1FB6AEA3-7ABE-4CAB-9C34-959B4C279511Q42269977-97F48A05-3022-4020-B59D-F0A050400241Q42506362-71D17979-B24C-462A-842A-F61FEDB20BD2Q42774378-645FCE74-54BF-45EC-BB20-F2602956C53AQ44643445-6A8BC5ED-9AF9-4C72-8D88-EA6A18435E3BQ45069154-3B43B1B4-1CEA-43E4-8A6A-9BDBAE0FA178Q46538042-9F4E9D0F-58CC-4D8E-9140-82F60FA8B737Q47135891-8D537D18-5D67-4855-9D44-9BFC6DAA65D8Q47141559-724DDBB0-3245-45FC-BEA3-0C8B8830E671Q47285585-70309A11-4911-4340-BB70-00D82E7BCCE7Q47559665-FD34B477-1761-484D-8126-9249D3C304A5Q47715159-0DF4004F-65A1-4C48-A6D1-98B202A0481BQ48022703-44A6E55B-5E4D-4DCD-AA40-D7899261F973Q48190808-AA1B1E50-5481-4100-868C-A7AE9356AE05Q49888000-6C79D346-4271-4571-947C-24EE9504BF79Q50078274-08206A22-1CBF-49F0-BC50-E42A3F286447
P2860
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
@en
type
label
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
@en
prefLabel
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
@en
P2093
P1476
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
@en
P2093
Brett N Tomson
Elisa Arthur
Jennifer Carter
Sheryl Elkin
Teresa Helsten
P304
P356
10.1158/1078-0432.CCR-14-3212
P407
P577
2015-09-15T00:00:00Z